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CMV reactivation has been associated with increased non-
relapsemortality (NRM)and improvedearly relapse incidence
(RI) post HLA matched allogeneic hematopoietic stem cell
transplant (HSCT), however, it’s effect has been less exten-
sively studied inTcell repletehaploidentical (HI)HSCT. In the2
step approach to HI HSCT developed at our institution, a large
ﬁxeddose of Tcells (2 x 108) is administered after conditioning
( Step 1), followed 2 days later bycyclophosphamide (CY) for T
cell tolerization. In Step 2, a CD34-selected stemcell product is
infused 1 day after completing CY. A signiﬁcant increase in T
cell numbers, especially in CD3/8 counts, was associated with
CMVreactivation inmanypatients treatedwith this approach.
We hypothesized that a CMV-associated increase in CD3/8
counts would impact HSCT outcomes.
A retrospective outcomes analysis (OS, NRM and RI) using
multivariable proportional hazards regression was per-
formed on all patients enrolled on a 2 step clinical trial since
2006, whowere alive and disease free at D90 (n¼106). High v
low CD3/8 count at D90, a history of GVHD treated with
steroids and CMV reactivation (deﬁned by > 100 copies/ml
by PCR) both by D90, were the factors of interest. Known
predictors of outcomes including disease at HSCT and he-
matopoietic comorbidity index (HCT CI) were included in the
analysis. The median CD3/8 count for the group, 125 cells/ul,
was used to differentiate CD8H v CD8L levels.
43% patients reactivated CMV prior to D90. The median
CD3/8 count for CMV-R (reactivators) v CMV-NR (non-
reactivators) was 308.4 v 53.7 cells/ul (p<0.0001). For the
whole group, CD8H had a signiﬁcant protective effect for OS
and NRM. CMV reactivation, disease at HSCT and higher HCT
CI score had a signiﬁcant negative impact. Table 1. No var-
iables were signiﬁcantly associated with RI. In a subset
analysis, patients with acute GVHD/CD8H had superior OS
in both CMV-R and CMV-NR groups. CMV-NR patients with
CD8L/no acute GVHD had the poorest OS. Fig 1. CMV-R
patients with CD8L had equally poor OS with or without
acute GVHD. Fig 2.
Higher CD3/8 counts were signiﬁcantly associated with
improved OS and lower NRM in all patients irrespective of
CMV reactivation. Higher CD3/8 counts in CMV-R patients
may mitigate the effects of CMV reactivation while preser-
ving the beneﬁcial effects of GVHD on OS, a ﬁnding that re-
quires further investigation. Prospective analyses of CD3/8
and CD3/4 numbers and strategies to increase them such as
early withdrawal of immunosuppression are warranted.Table 1
Multivariable model for OS
Variable Comparison Hazard Ratio (95% CI) p-value
CMV D90 R v NR 3.28 (1.19,9.05) 0.022
CD8 D90 CD8L v CD8H 3.87 (1.39,10.8) 0.0096
GVHD/Steroid D90 Y v N 0.71 (0.32,1.57) 0.40
Dz at HSCT N v Y 0.27 (0.11,0.65) 0.0036
HCTCI 1 unit increase 1.43 (1.08,1.90) 0.013
Age 1 year increase 0.99 (0.97,1.02) 0.60
Conditioning Myelo v RIC 1.36 (0.63,2.94) 0.44205
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Graft failure (GF) after hematopoietic cell transplant (HCT)
occurs in 5-30[DW1] % of patients. GF can be accompanied by
neutropenia (NGF)or can resultwithadequateneutrophils, but
loss ofdonor chimerism (non-neutropenic graft failure,NNGF).
We analyzed the outcomes of 61 patients (pediatric and adult)
treated with a second HCT for GF at the University of Minne-
sota; 27withNGFand34withNNGF. The cumulative incidence
of neutrophil engraftment at 42days after secondHCTwas88%
forNNGF, and 68% forNGF (p¼0.03). The incidence of grade III-
IV acute graft versus host disease (GVHD) was 15% (95% con-
ﬁdence interval (CI), 2 e 28%) and 6% (95% CI, 2 - 17%) for NGF
and NNGF, respectively (p ¼ 0.17). From the 2ndHCT, 1-year
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S167overall survival (OS) was 54% (95% CI, 41e66%) for the entire
cohort with an OS for NNGF of 73% (95% CI, 55 e 85%) and for
NGF OS was 30% (95% CI, 14e47%) (p<0.01). A second GF
occurred in 18 (67%) NGF and in 9 (26%) NNGF patients. Viral
studies showed there was more frequent HHV6 reactivation,
with 48% of the NGF group versus 8.8% of the NNGF group (p<
0.01) having reactivation. EBV and CMV reactivate was not
different. The most common cause of death after second HCT
was persisting GF leading to infection or infection despite
engraftment. Outcomes of second HCT for NGF and NNGF are
different with very poor outcomes for the NGF group, neces-
sitating new approaches to improve overall survival.206
Prolonged Stimulation-Induced Pro-Apoptotic B Cells
and Deﬁcits in the Germinal Center Formation of Memory
B Cells within One Year after Allogeneic HSCT
Angela Mensen 1, Youngseong Oh 1, Philipp Hemmati 2,
Christian Jehn 2, Jörg Westermann 2, Lam Vuong 2,
Bernd Dörken 2,3, Carmen Scheibenbogen 1, Renate Arnold 2,
Il-Kang Na 2,4. 1 Institute for Medical Immunology, Charité -
Universitätsmedizin Berlin, Berlin, Germany; 2Hematology,
Oncology and Tumor Immunology, Charité -
Universitätsmedizin Berlin, Berlin, Germany; 3Max Delbrück
Center (MDC) for Molecular Medicine, Berlin, Germany;
4 Experimental and Clinical Research Center (ECRC), Charité -
Universitätsmedizin Berlin, Berlin, Germany
B-cell immune dysfunction substantially contributes to the
risk of severe infections after allogeneic hematopoietic stem
cell transplantation (alloHSCT). B-cell numbers normalize
within one year after transplantation, howevermanypatients
display a slow recovery of CD27+ memory B cells and week
vaccination responses. Little is known about functional B-cell
deﬁcits associated with memory deﬁciency post-transplant.
In our study we quantitatively and phenotypically
analyzed B- and T-cell subsets in peripheral blood by ﬂow
cytometry at days 180 and 360 after alloHSCT in acute
leukemic patients (n¼36). In addition, apoptosis of B-cell
subsets was investigated after stimulation with CpG and
CD40L. To address the B-cell milieu cytokines and chemo-
kines were measured with Luminex technology.
Half of patients at day 180 and all patients at day 360 dis-
played fully restored absolute B-cell numbers, although
CD27+ memory B-cell subsets remained diminished (cells/
mlSEM: healthy control (HC) 264, alloHSCT 41;
p0.001). All B-cell subsets were characterized by an acti-
vated/pro-apoptotic phenotype with an increased CD86 and
Fas but reduced Baff-R expression at day 180. Accordingly, an
inﬂammatory milieu was present with increased serum
levels of TNFa, IFNa2, G-CSF, IP-10, MCP-1, MIP-1b and
Eotaxin in patients compared to HC. While CD86 normalized
at day 360 on most B-cell subsets, all subsets retained a
strong pro-apoptotic phenotype with increased Fas and
reduced Baff-R expression. Interestingly, stimulation of pe-
ripheral blood mononuclear cells with CpG and CD40L
resulted in signiﬁcantly increased percentages of apoptotic
cells for the patients compared to HC (% of B cellsSEM: HC
112, alloHSCT 285 day180, 606 day 360; p0.001).
Regarding the lack of CD27+ memory B-cell recovery, we
assumed a defective germinal center (GC) reaction. Supporting
this suggestion we found (A) a reduced CXCR5 expression on
naïve B cells, important for the entry into B-cell follicles
(MFISEM:HC 5899975, alloHSCT 3494554; p0.01), (B) a
low HLA-DR expression on naïve B cells, essential for antigen
presentation (HC204404742, alloHSCT91502386;p0.01),
(C) a normalnumberof CD27-IgD- doublenegative (DN) B cells,suggested to prematurely leave the GC reaction, (D) a
remaining CD4+ T-cell deﬁciency (cells/mlSEM: HC 97277,
alloHSCT 30345; p0.001) and (E) a reduced percentage of
circulating CXCR5+ follicular T helper cells, importantly
involved in GC reactions (%SEM: HC 62, alloHSCT 21).
We conclude that a sustained inﬂammatory milieu and
possibly damage within lymphoid organs might contribute
to a prolonged pro-apoptotic state of B-cell subsets and de-
fects in the GC reaction long-term after allo-HSCT. Despite
normal total B-cell numbers signiﬁcant functional deﬁcits
exist more than one year after transplant, so that adoptive
transfer of memory CD27+ B cells should be pursued.207
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Introduction: Favorable IR after allo-SCT has been reported
after reduced intensity conditioning (RIC); however, T-cell
depletion and cord blood (CB) SCT have been associated with
delay in IR. The goal of this study is to compare the rates of IR
using three different transplant strategies employed at
UMass Memorial Medical Center.
Patients & Methods: We retrospectively analyzed data of all
patients who underwent allo-SCT at our institution since April
2009 using either RIC with thiotepa/ﬂudarabine/melphalan
followed by post-transplant cylophosphamide (TFM/Cy arm),
RIC with Fludarabine/Busulfanx2/antithymocyte globulin
(FluBu2/ATG arm) or CB transplant with TFM/ATG regimen. IR
was assessed by rates of recovery of lymphocyte subsets
(CD3, CD4, CD19, CD25+127- and NK-cells) and serum
immunoglobulins (Ig’s)atD30,D100and1yearpost transplant.
Results: 102 patients were identiﬁed from the database. 38
patients (37.2%) were included in the TFM/Cy arm, 38 pa-
tients (37.2%) in the FluBu2/ATG arm and 26 patients (25.5%)
in the CB arm. Median age of all patients was 62.2 years
(range 18.4 e 83.5) and 52.4, 67.5, and 63 years in the TFM/
Cy, FluBu2/ATG and CB arms, respectively. Median lympho-
cyte subset counts and Ig levels at different post transplant
points are detailed in Table 1. CD3 and CD4 recovery was
signiﬁcantly inferior in the CB arm at D30 and D100. There
was a trend towards delayed IR of regulatory T-cells
(CD25+127-) in the CB arm at all points. CD19 and NK-cell
recovery was superior in the CB arm at all points, but NK-
cell recovery did not reach statistical signiﬁcance at 1 year.
Recovery of serum Ig’s was noted to be faster in the
FluBu2/ATG arm early on post transplant. At 1-year post
allo-SCT, Ig values were comparable in all arms.
